Affirmed Therapeutics BV (AFMD) Short Interest Down 24.5% in September
Affirmed Therapeutics BV (NASDAQ:AFMD) saw a large decrease in short interest in September. As of September 30th, there was short interest totalling 752,570 shares, a decrease of 24.5% from the September 15th total of 996,488 shares. Based on an average daily volume of 147,751 shares, the short-interest ratio is currently 5.1 days. Approximately 4.1% of the company’s shares are short sold.
Shares of Affirmed Therapeutics BV (NASDAQ:AFMD) opened at 2.34 on Friday. The firm’s 50-day moving average is $2.70 and its 200 day moving average is $3.19. The stock’s market cap is $78.36 million. Affirmed Therapeutics BV has a 12 month low of $2.25 and a 12 month high of $8.26.
Affirmed Therapeutics BV (NASDAQ:AFMD) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.05. Affirmed Therapeutics BV had a negative net margin of 440.97% and a negative return on equity of 49.84%. The firm had revenue of $2.07 million for the quarter, compared to analysts’ expectations of $2.10 million. During the same period in the prior year, the firm earned ($0.19) EPS. Affirmed Therapeutics BV’s revenue for the quarter was down 6.4% compared to the same quarter last year. On average, equities analysts predict that Affirmed Therapeutics BV will post ($1.12) EPS for the current year.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Affirmed Therapeutics BV from a “hold” rating to a “sell” rating in a research note on Wednesday. Leerink Swann cut shares of Affirmed Therapeutics BV from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $8.00 to $3.00 in a research note on Friday, August 12th. Finally, Jefferies Group reaffirmed a “hold” rating on shares of Affirmed Therapeutics BV in a research note on Tuesday, August 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $8.63.
A number of institutional investors have recently modified their holdings of AFMD. Lombard Odier Asset Management USA Corp increased its position in shares of Affirmed Therapeutics BV by 4.7% in the second quarter. Lombard Odier Asset Management USA Corp now owns 365,677 shares of the biopharmaceutical company’s stock valued at $907,000 after buying an additional 16,555 shares in the last quarter. Paloma Partners Management Co purchased a new position in shares of Affirmed Therapeutics BV during the second quarter valued at $142,000. Perceptive Advisors LLC purchased a new position in shares of Affirmed Therapeutics BV during the second quarter valued at $1,821,000. Opaleye Management Inc. increased its position in shares of Affirmed Therapeutics BV by 2.5% in the first quarter. Opaleye Management Inc. now owns 610,000 shares of the biopharmaceutical company’s stock valued at $2,281,000 after buying an additional 15,000 shares in the last quarter. Finally, Moore Capital Management LP purchased a new position in shares of Affirmed Therapeutics BV during the first quarter valued at $281,000. 42.86% of the stock is currently owned by institutional investors and hedge funds.
Affirmed Therapeutics BV Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affirmed Therapeutics BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affirmed Therapeutics BV and related companies with MarketBeat.com's FREE daily email newsletter.